Skip to main content

Table 3 Infection characteristics, treatment and outcomes

From: Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis

 

CSE

%

CRE

%

P-value

N = 38,910

N = 1227

Infection characteristics

 Sepsis

12,726

32.7%

409

33.3%

0.039

 Pneumonia

5060

13.0%

187

15.2%

 UTI

21,124

54.3%

631

51.4%

 HCA

13,782

35.4%

718

58.5%

<0.001

Illness severity measures by day 2

 ICU admission

15,876

40.8%

687

56.0%

<0.001

 Mechanical ventilation

6092

15.7%

437

35.6%

<0.001

 Vasopressors

5798

14.9%

205

16.7%

0.081

Antibiotics administered by day 2

 Aminoglycosides

3843

9.9%

242

19.7%

<0.001

 Antipseudomonal penicillins

6403

16.5%

313

25.5%

<0.001

 Antipseudomonal floroquinolones

18,468

47.5%

406

33.1%

<0.001

 Antipseudomonal penicillins with beta-lactamase inhibitors

19,727

50.7%

617

50.3%

0.775

 Extended spectrum cephalosporins

13,327

34.3%

415

33.8%

0.755

 Folate pathway inhibitors

251

0.6%

12

1.0%

0.155

 Penicillins with beta-lactamase inhibitors

854

2.2%

26

2.1%

0.837

 Polymyxins

126

0.3%

24

2.0%

<0.001

 Tetracyclines

248

0.6%

6

0.5%

0.519

 Tigecycline

586

1.5%

86

7.0%

<0.001

 Aztreonam

1740

4.5%

56

4.6%

0.878

Empiric treatment appropriateness

 Non-IET

32,197

82.7%

513

41.8%

<0.001

 IET

4336

11.1%

648

52.8%

 Indeterminate

2337

6.0%

66

5.4%

Hospital outcomes

 Mortality

3958

10.2%

178

14.5%

<0.001

 Mean (SD) LOS, days

9.6 (10.7)

 

15.6 (17.4)

 

<0.001

 Median [IQR] LOS, days

7 [4, 11]

 

10 [6, 18]

 

<0.001

 Mean (SD) costs, $

20,601 (29702)

 

38,494 (46,964)

 

<0.001

 Median [IQR] costs, $

13,020 [7501, 24,237]

 

22,909 [12,988, 42,815]

 

<0.001

Hospital outcomes stratified by infection type

 UTI

  Mortality

1873

8.9%

78

12.4%

0.002

  Mean (SD) LOS, days

9.0 (9.4)

 

14.6 (15.9)

 

<0.001

  Median [IQR] LOS, days

7 [4, 11]

 

10 [6, 17]

 

<0.001

  Mean (SD) costs, $

19,036 (24,494)

 

33,400 (37,662)

 

<0.001

  Median [IQR] costs, $

12,082 [7104, 21,822]

 

21,154 [12,687, 39,374]

 

<0.001

 Sepsis

  Mortality

1660

13.0%

81

19.8%

<0.001

  Mean (SD) LOS, days

10.9 (12.6)

 

18.0 (20.8)

 

<0.001

  Median [IQR] LOS, days

7 [4, 13]

 

11 [7, 21]

 

<0.001

  Mean (SD) costs, $

26,793 (37,390)

 

50,038 (60,602)

 

<0.001

  Median [IQR] costs, $

15,614 [8584, 30,317]

 

27,264 [14,581, 57,825]

 

<0.001

 Pneumonia

  Mortality

425

8.4%

19

10.2%

0.395

  Mean (SD) LOS, days

9.2 (10.4)

 

13.4 (13.0)

 

<0.001

  Median [IQR] LOS, days

7 [4, 10]

 

9 [6, 16]

 

<0.001

  Mean (SD) costs, $

19,250 (25,743)

 

30,432 (35,089)

 

<0.001

  Median [IQR] costs, $

11,826 [7076, 21,100]

 

19,820 [12,220, 35,713]

 

<0.001

  1. CSE carbapenem sensitive Enterobacteriaceae, CRE carbapenem resistant Enterobacteriaceae, UTI urinary tract infection, HCA healthcare-associated, ICU intensive care unit, IET inappropriate empiric therapy